CRIS Current Research Information System

NANNI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.351
AS - Asia 4.813
EU - Europa 4.003
AF - Africa 343
Continente sconosciuto - Info sul continente non disponibili 325
SA - Sud America 244
OC - Oceania 10
Totale 16.089
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.228
VN - Vietnam 1.531
CN - Cina 1.247
SG - Singapore 1.105
IT - Italia 1.019
GB - Regno Unito 884
DE - Germania 471
HK - Hong Kong 329
SE - Svezia 314
FR - Francia 224
RU - Federazione Russa 206
IN - India 185
UA - Ucraina 180
BR - Brasile 171
CH - Svizzera 143
IE - Irlanda 123
NL - Olanda 121
CI - Costa d'Avorio 113
ZA - Sudafrica 106
JP - Giappone 90
CA - Canada 84
BD - Bangladesh 69
EE - Estonia 58
FI - Finlandia 57
TG - Togo 56
KR - Corea 53
BG - Bulgaria 44
BE - Belgio 43
AR - Argentina 33
SC - Seychelles 29
ID - Indonesia 26
PH - Filippine 25
TH - Thailandia 22
MX - Messico 20
JO - Giordania 19
TR - Turchia 19
IQ - Iraq 18
LT - Lituania 17
PL - Polonia 16
RO - Romania 15
EC - Ecuador 14
TW - Taiwan 13
AT - Austria 12
CL - Cile 11
NG - Nigeria 11
PK - Pakistan 11
EG - Egitto 10
ES - Italia 10
AU - Australia 8
GR - Grecia 8
HR - Croazia 8
IR - Iran 7
SA - Arabia Saudita 7
CO - Colombia 6
AE - Emirati Arabi Uniti 5
DK - Danimarca 5
MA - Marocco 5
MY - Malesia 5
EU - Europa 4
JM - Giamaica 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CZ - Repubblica Ceca 2
GH - Ghana 2
GP - Guadalupe 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LI - Liechtenstein 2
LV - Lettonia 2
MD - Moldavia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
DM - Dominica 1
ET - Etiopia 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
Totale 15.756
Salva come PNG Salva come JPEG
Città #
Singapore 744
Southend 719
Fairfield 685
Ashburn 651
Chandler 528
Ho Chi Minh City 335
Wilmington 317
Hong Kong 313
Houston 310
Woodbridge 310
Ann Arbor 296
Hanoi 284
San Jose 270
Bologna 260
Seattle 256
Cambridge 205
Dong Ket 191
Santa Clara 190
Shanghai 184
Princeton 175
Beijing 137
Boardman 127
Hefei 125
Dublin 122
Council Bluffs 121
Jacksonville 118
Abidjan 113
Bern 113
Dallas 85
Los Angeles 79
Lauterbourg 77
Nanjing 75
Tokyo 74
Westminster 74
New York 73
Milan 66
Padova 66
Lomé 56
Berlin 55
Bremen 50
Haiphong 48
Guangzhou 46
Jinan 44
Buffalo 43
Helsinki 43
Sofia 43
Saint Petersburg 42
Brussels 41
Seoul 39
San Diego 37
Shenyang 37
Redwood City 36
Da Nang 35
Frankfurt am Main 34
Johannesburg 34
London 30
Phoenix 29
Redmond 29
Turin 29
Nanchang 28
Redondo Beach 28
Changsha 27
São Paulo 27
Toronto 27
Hebei 26
Rome 25
Tianjin 25
Mülheim 24
Casalecchio di Reno 23
Falkenstein 22
Jakarta 22
Ottawa 22
Amsterdam 21
Amman 19
Jiaxing 19
Hải Dương 18
Zhengzhou 18
Falls Church 17
Bulle 15
Mahé 15
Montreal 15
Atlanta 14
Bengaluru 14
Biên Hòa 14
Des Moines 14
Hangzhou 13
Can Tho 12
Shijiazhuang 12
Haikou 11
Yubileyny 11
Abeokuta 10
Bắc Giang 10
Bến Tre 10
Nuremberg 10
Orem 10
Stockholm 10
Verona 10
Warsaw 10
Bühl 9
Dearborn 9
Totale 10.444
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 441
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 386
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 344
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 325
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 273
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 268
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 264
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 263
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 259
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 257
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 248
Rethinking herpes simplex virus: the way to oncolytic agents. 239
Virus-like particle display of HER2 induces potent anti-cancer responses 233
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 232
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 231
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 223
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 219
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 217
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 217
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
CD99 Acts as an Oncosuppressor in Osteosarcoma. 216
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 215
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 211
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 209
Cancer immunoprevention: from mice to early clinical trials 208
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 203
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 202
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 202
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 201
In silico modeling and in vivo efficacy of cancer preventive vaccinations 200
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 199
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 194
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 190
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 189
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 188
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 188
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 188
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 187
Antimetastatic activity of a preventive cancer vaccine. 187
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 186
Oncolytic herpes virus retargeted to HER-2. 182
Herpesviruses as oncolytic agents 182
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 181
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 179
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 178
Modeling the competition between lung metastases and the immune system using agents. 178
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 177
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 177
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 175
Immunoprevention and immunotherapy of mammary carcinoma 174
The Promise of Preventive Cancer Vaccines 173
Vaccines for tumour prevention 172
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 169
Immunological prevention of a multigene cancer syndrome 166
The molecular basis of herpesviruses as oncolytic agents. 163
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 163
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 162
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 162
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 160
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 159
New target antigens for cancer immunoprevention 155
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 151
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 150
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 150
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 149
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 149
2011: the immune hallmarks of cancer 148
Preclinical vaccines against mammary carcinoma. 148
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 147
Molecular and cellular biology of rhabdomyosarcoma 145
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 144
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 141
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer 138
Vaccines and other immunological approaches for cancer immunoprevention 137
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. 124
Immunoprevention 123
Cancer biology, what we know and what we don't know. 121
Methods of treating bone cancer 115
Immunoprevention of cancer 101
null 99
Vaccini contro i tumori 97
Immunotherapy 95
Cancer immunoprevention 85
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 84
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 71
null 62
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. 59
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture 34
HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody 17
Totale 16.089
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.294
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.294
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.528 0 67 145 82 155 110 51 111 73 115 367 252
2022/20231.986 233 238 106 271 137 137 65 104 261 106 161 167
2023/2024637 22 75 45 51 37 75 35 217 10 27 14 29
2024/20251.954 153 223 154 102 334 134 125 85 22 134 93 395
2025/20264.769 496 455 395 350 475 245 403 145 961 431 209 204
2026/2027185 127 58 0 0 0 0 0 0 0 0 0 0
Totale 16.089